注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Spero Therapeutics Inc是一家临床阶段的生物制药公司。该公司专注于识别、开发和商业化涉及细菌感染的治疗,包括多药耐药(MDR)细菌感染,以及存在未满足医疗和患者需求的罕见疾病。其主要候选产品tebipenem pivoxil hydrobromide(tebipenem HBr)被设计为第一种口服碳青霉烯类抗生素,用于治疗导致复杂尿路感染(cUTIs)的某些细菌感染,包括由某些微生物引起的肾盂肾炎,在口服治疗选择有限的成年患者中。该公司的管道还包括SPR720和SPR206。SPR220旨在成为非结核分枝杆菌(NTM)感染的首个口服治疗。SPR206是一种直接作用静脉注射(IV)多粘菌素类似物,由其增强剂平台开发,用于治疗医院内的耐多药革兰氏阴性细菌感染。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Eric M. Gordon | - | 2014 | Scientific Advisors |
George L. Drusano | - | 2014 | Clinical Advisor |
Scott T. Jackson | 58 | 2020 | Independent Director |
Paul G. Ambrose | - | 2014 | Clinical Advisor |
Gordon L. Archer | 79 | 2014 | Clinical Advisor |
Kathleen Tregoning | 52 | 2021 | Independent Director |
Keith A. Rodvold | - | - | Clinical Advisor |
Milind S. Deshpande | 66 | 2014 | Independent Director |
Patrick V. J. J. Vink | 60 | 2015 | Lead Independent Director |
Martti Vaara | - | - | Scientific Advisor |
Richard C. White | - | - | Scientific Advisor |
William Hope | - | - | Clinical Advisor |
Paul Francis Miller | 63 | - | Scientific Advisor |
Cynthia Smith | 54 | 2019 | Independent Director |
Steven C. Gilman | 70 | - | Scientific Advisor |
Frank E. Thomas | 53 | 2017 | Independent Director |
John C. Pottage | 70 | 2018 | Independent Director |
Helen W. Boucher | - | - | Clinical Advisor |
Jeffrey L. Stein | 68 | - | Scientific Advisor |
James B. Kahn | - | - | Clinical Advisor |
David Livermore | - | - | Scientific Advisor |
Ankit Mahadevia | 43 | 2013 | Co-Founder & Chairman of the Board |
Satyavrat Shukla | 51 | 2021 | President, CEO & Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核